Energy · Projected milestone
Fusion neutron foundries sell useful isotopes
20% by 2080 · including earlier years
The year is an editorial timing estimate. The percentage applies to occurrence by the stated deadline. These estimates are not calibrated odds.
Fusion-driven neutron facilities commercially deliver three non-fuel isotopes for medical, scientific or industrial customers over five consecutive years, with independent accounts showing positive operating margin after feedstock, separation, radiation protection and waste costs, and at least 10% of the documented addressable market supplied for one product.
Explore this milestone on the interactive mapWhat the forecast means
Milestone stage: sustained commercial operation
Isotope production is established by other routes; profitable multi-product fusion-driven supply is a modeled possibility.
Timing window: 2035–2080. An editorial range, not a statistical confidence interval.
Completion criteria: Fusion-driven neutron facilities commercially deliver three non-fuel isotopes for medical, scientific or industrial customers over five consecutive years, with independent accounts showing positive operating margin after feedstock, separation, radiation protection and waste costs, and at least 10% of the documented addressable market supplied for one product. Resolve only after inspectable dated observations and independent assessment meet every stated criterion; a simulation, announcement or prototype lacking these thresholds does not resolve the event.
This page describes a forecast, rather than an achieved result. Read the methodology and assumptions.
Built on
Led to
- Nuclear waste transmutedForecast · ~2063influences
- Fusion power fleetsForecast · ~2064influences
Sources & evidence
- Isotope Production in Fusion Systems 2026-03-22
A theoretical economic analysis explores neutron transmutation products from fusion systems, including operation below energy breakeven. Revenue and market claims are modeled, not audited commercial outcomes.
- DOE Isotope R&D and Production
DOE produces and develops isotopes for medical, research and industrial uses. Existing isotope markets do not demonstrate competitive fusion-driven production.
Astra editorial synthesis; cited researchers retain credit for their work
Record reviewed 2026-10-18